Matrix delivery transdermal 17beta-estradiol for the prevention of bone loss in postmenopausal women. The International Study Group.
A total of 277 early postmenopausal women were enrolled in this placebo-controlled 2-year study to examine the efficacy of a matrix transdermal 17beta-estradiol system, at three different dosages (25, 50 and 75 mg/day) combined with sequential oral dydrogesterone 20 mg/day, in preventing bone loss....
Autors principals: | Cooper, C, Stakkestad, J, Radowicki, S, Hardy, P, Pilate, C, Dain, M, Delmas, P |
---|---|
Format: | Journal article |
Idioma: | English |
Publicat: |
1999
|
Ítems similars
-
Matrix delivery transdermal 17 beta-estradiol for the prevention of bone loss in postmenopausal women
per: Cooper, C, et al.
Publicat: (1999) -
Effect of continuous transdermal-estradiol and norethisterone acetate vs estradiol transdermal HRT on bone markers in postmenopausal women
per: Cooper, C, et al.
Publicat: (2000) -
Percutaneous 17ß-estradiol replacement therapy in hypertensive postmenopausal women
per: M.C. Osório-Wender, et al.
Publicat: (1997-09-01) -
Docosahexaenoic acid and 17 beta-estradiol co-treatment is more effective than 17 beta-estradiol alone in maintaining bone post-ovariectomy.
per: Poulsen, R, et al.
Publicat: (2008) -
Regulated expression of matrix metalloproteinases, inflammatory mediators, and endometrial matrix remodeling by 17beta-estradiol in the immature rat uterus
per: Caruso Joseph A, et al.
Publicat: (2009-11-01)